Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Z Leder

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 8, 2023
Correction to: The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trialSabashini K Ramchand, Joy N Tsai, Hang Lee, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 15, 2014
Teriparatide (PTH 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal womenElaine W Yu, Ruchit Kumbhani, Erica Siwila-Sackman, et al.
Journal of the Endocrine Society|March 29, 2024
A Fracture Liaison Service to Address Vitamin D Deficiency for Patients Hospitalized for Osteoporotic FractureXiaoxu Sun, Benjamin Z Leder, Marcy B Bolster, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 8, 2011
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
The Journal of Clinical Endocrinology and Metabolism|May 2, 2015
Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or AlendronateJoy N Tsai, Yuli Zhu, Katelyn Foley, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 14, 2020
Effects of Combination Denosumab and High-Dose Teriparatide Administration on Bone Microarchitecture and Estimated Strength: The DATA-HD HR-pQCT StudySabashini K Ramchand, Natalie L David, Hang Lee, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 5, 2022
The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study ExtensionSabashini K Ramchand, Natalie L David, Hang Lee, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 15, 2019
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend TrialBenjamin Z Leder, Carol Zapalowski, Ming-Yi Hu, et al.
The Journal of Clinical Endocrinology and Metabolism|May 14, 2009
Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosisBenjamin Z Leder, Robert M Neer, Jason J Wyland, et al.
The Journal of Urology|October 20, 2009
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 8, 2023
Correction to: The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trialSabashini K Ramchand, Joy N Tsai, Hang Lee, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 15, 2014
Teriparatide (PTH 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal womenElaine W Yu, Ruchit Kumbhani, Erica Siwila-Sackman, et al.
Journal of the Endocrine Society|March 29, 2024
A Fracture Liaison Service to Address Vitamin D Deficiency for Patients Hospitalized for Osteoporotic FractureXiaoxu Sun, Benjamin Z Leder, Marcy B Bolster, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 8, 2011
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
The Journal of Clinical Endocrinology and Metabolism|May 2, 2015
Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or AlendronateJoy N Tsai, Yuli Zhu, Katelyn Foley, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 14, 2020
Effects of Combination Denosumab and High-Dose Teriparatide Administration on Bone Microarchitecture and Estimated Strength: The DATA-HD HR-pQCT StudySabashini K Ramchand, Natalie L David, Hang Lee, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 5, 2022
The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study ExtensionSabashini K Ramchand, Natalie L David, Hang Lee, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 15, 2019
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend TrialBenjamin Z Leder, Carol Zapalowski, Ming-Yi Hu, et al.
The Journal of Clinical Endocrinology and Metabolism|May 14, 2009
Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosisBenjamin Z Leder, Robert M Neer, Jason J Wyland, et al.
The Journal of Urology|October 20, 2009
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
Pageof 9